These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 14555232)

  • 1. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis.
    Zhang XD; Gillespie SK; Borrow JM; Hersey P
    Biochem Pharmacol; 2003 Oct; 66(8):1537-45. PubMed ID: 14555232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
    Gillespie S; Borrow J; Zhang XD; Hersey P
    Apoptosis; 2006 Dec; 11(12):2251-65. PubMed ID: 17051334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells.
    Zhang XD; Gillespie SK; Borrow JM; Hersey P
    Mol Cancer Ther; 2004 Apr; 3(4):425-35. PubMed ID: 15078986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation.
    Neuzil J; Swettenham E; Gellert N
    Biochem Biophys Res Commun; 2004 Jan; 314(1):186-91. PubMed ID: 14715264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
    BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
    Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K
    Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
    Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
    Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
    Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
    Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A
    Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antitumor activity of histone deacetylase inhibitor suberic bishydroxamate on acute myeloid leukemia cell lines].
    Xu YH; Yang CM; Qian WB
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):491-7. PubMed ID: 23086640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria.
    Thomas WD; Zhang XD; Franco AV; Nguyen T; Hersey P
    J Immunol; 2000 Nov; 165(10):5612-20. PubMed ID: 11067917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
    Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
    Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.
    Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P
    Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
    Rosato RR; Almenara JA; Dai Y; Grant S
    Mol Cancer Ther; 2003 Dec; 2(12):1273-84. PubMed ID: 14707268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.
    Fandy TE; Shankar S; Ross DD; Sausville E; Srivastava RK
    Neoplasia; 2005 Jul; 7(7):646-57. PubMed ID: 16026644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
    Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M
    Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X; Li H
    Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK; VanOosten RL; Griffith TS
    Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
    Facchetti F; Previdi S; Ballarini M; Minucci S; Perego P; La Porta CA
    Apoptosis; 2004 Sep; 9(5):573-82. PubMed ID: 15314285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.